Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...
GlobalData on MSN4d
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP useThe US Food and Drug Administration (FDA) has accepted Gilead’s new drug application (NDA) for lenacapavir and set a ...
News Medical on MSN3d
New HIV therapy lenacapavir shows high efficacy in Ugandan populationA multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
A new HIV drug, lenacapavir, appears highly effective against strains circulating in Uganda, according to a study led by ...
Twice-yearly lenacapavir PrEP could be available as early as this summer pending federal Food and Drug Administration ...
Join the live Q&A on PrEP, the latest in HIV prevention. Text your questions to 713-526-1111 and tune in Monday to learn ...
The Food and Drug Administration (FDA) has accepted under Priority Review the New Drug Application (NDA) for lenacapavir, a long-acting HIV-1 capsid inhibitor, for the prevention of HIV as ...
A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.
Gilead is edging closer to an approval for its twice-yearly injectable human immunodeficiency virus-1 (HIV-1) capsid inhibitor, lenacapavir, as a pre-exposure prophylaxis (PrEP) option.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback